Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Topline data anticipated in October 2020 as previously guided Topline data anticipated in October 2020 as previously guided

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vaccinex Inc (VCNX) Reports Q1 Loss, Lags Revenue Estimates

Approaching key topline data in non-small cell lung cancer and Huntington’s disease

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

Data continue to demonstrate durable response in patients as trial nears completion Data continue to demonstrate durable response in patients as trial nears completion

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vaccinex Inc (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen

Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease

Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies  AAT-AD/PD™ Focus Meeting 2020

Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data

Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease

Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation

ROCHESTER, N.Y., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepinemab in combination anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) were reported during podium and poster presentations on Friday, September 27 at the Fifth International Cancer lmmunotherapy Conference held in Paris, France.   The International Cancer lmmunotherapy Conference (CICON2019) is a premier immuno-oncology event and is presented by the Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR).

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in

ROCHESTER, N.Y., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive Officer, will present a corporate overview and business update at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24th in New York City. Dr. Zauderer will review updated interim data of the Phase 1b/2 study of pepinemab, VX15 anti-semaphorin 4D antibody, in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of Vaccinex’s ongoing, potentially pivotal study of pepinemab as a single agent to treat Huntington’s disease. Further details of the NSCLC study will be presented on Friday, September 27 at the Fifth International Cancer lmmunotherapy Conference to be held in Paris, France.

Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share.

Vaccinex Inc (VCNX) President and CEO Maurice Zauderer Bought $750,002 of Shares

News for Vaccinex Inc Stock (VCNX)